Skip to main content
. 2015 Mar;185(3):704–716. doi: 10.1016/j.ajpath.2014.11.021

Figure 2.

Figure 2

Genetic or pharmacological inhibition of protein S6 kinase, 90 kDa, polypeptide 1 (RSK1) inhibits nodular melanoma (NM) but not superficial spreading melanoma (SSM) cell proliferation. A: Western blot analysis showing RSK1 levels after transfection with nontargeting (N.T.), RSK1-targeting, or RSK2-targeting siRNA in WM 1552 melanoma cells (SSM). B: Crystal violet proliferation assay of SSM cells 48 hours after transient transfection with RSK1 or RSK2 siRNA or 72 hours after treatment with escalating doses of the RSK inhibitor BI-D1870. Data were normalized by setting N.T. siRNA-transfected or dimethyl sulfoxide (DMSO)–treated cells to 100%. C: Same as in A but using WM 3248 melanoma cells (NM). D: Same as in B but using NM cell lines. Data are given as means ± SEM. ∗∗P < 0.01, ∗∗∗P < 0.001 compared with N.T. siRNA-transfected cells.